bioAffinity Technologies (BIAF)
Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.
Something off on this page? Send us feedback.
Provides clinical pathology services and CyPath Lung, a sputum-based laboratory-developed test that helps physicians assess high-risk patients with suspicious lung nodules. Nearly all revenue flows through the San Antonio laboratory, the sole commercial provider of CyPath Lung.
Combines Precision Pathology Laboratory Services, a San Antonio clinical-pathology laboratory, with CyPath Lung, a sputum-based test using flow cytometry and automated analysis to aid physicians evaluating high-risk adults with small or indeterminate pulmonary nodules. The laboratory also supplies anatomic and clinical pathology services, with samples sent overnight from across the United States to its sole processing site.
Generates nearly all revenue through laboratory services, including patient, histology, and medical-director fees, while its diagnostic R&D segment supports observational studies and research-stage asthma/COPD diagnostics. CyPath Lung is offered as an LDT through the CAP-accredited, CLIA-certified laboratory rather than under FDA marketing authorization; reimbursement, state permissions, courier logistics, and the San Antonio facility are core operating dependencies.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.4M · Total debt $1.4M · Total assets $7.6M · Shareholders' equity $3.8M
- Revenue
- $1.5M
- Operating income
- −$3.3M
- Net income
- −$3.4M
No dividends on record.
| Institutions | 9.95% | 53.7K shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 0.65% | 3.5K shares | |
| 5 holders · as of Jan 14, 2025 | |||
| Other | 89.40% | 482.9K shares | |
| remainder | |||
540.1K company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (540.1K in the company's Sep 22, 2026 report, 418.9K elsewhere); stakes use the report.
1 position filed across a stock split leaves its adjustment unstated and stays out of the bar.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sabby Management, LLCInstitution | 4.51% | 365,647 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.22% | 98,777 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.69% | 55,543 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.63% | 50,967 | as of Jun 30, 2026 |
J. Safra Sarasin Holding AGInstitution | 0.53% | 42,600 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Biodesix
Blood-based lung-nodule tests contest the same diagnostic decision.
- Veracyte
A nasal genomic test targets the same indeterminate lung nodules.
- Quest Diagnostics
National laboratory and hospital-management services overlap with PPLS.
- Labcorp
National anatomic-pathology capacity contests PPLS laboratory services.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| bioAffinity Technologies | $8.51 | −0.93% | $3.2M | — | — | 0.5 | +19.0% |
| Biodesix | $28.15 | +0.68% | $231.4M | — | — | 2.2 | +34.2% |
| Veracyte | $43.36 | 0.00% | $3.31B | 29.7 | 23.9 | 5.9 | +15.5% |
| Quest Diagnostics | $234.76 | −0.04% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Labcorp | $311.54 | +0.05% | $26.32B | 26.6 | 16.4 | 1.8 | +5.8% |
| Median | 26.6 | 20.5 | 2.3 | +12.8% |